Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 5/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259795 | 1.00 | EPHX1 (0.48) | EPHX1ALDH1A1TP53HRH2HRH4 | |
| SCHEMBL13999779 | 1.00 | EPHX1 (0.48) | EPHX1ALDH1A1TP53HRH2HRH4 | |
| SCHEMBL20358270 | 0.89 | — | — | |
| SCHEMBL14000059 | 0.86 | ALDH1A1 (0.37) | EPHX1ALDH1A1HRH2HRH4HRH3 | |
| SCHEMBL6769503 | 0.83 | ALDH1A1 (0.42) | EPHX1ALDH1A1TP53CA12CA1 | |
| SCHEMBL1208925 | 0.81 | ALDH1A1 (0.55) | EPHX1ALDH1A1CA12CA1CA2 | |
| SCHEMBL6808670 | 0.81 | ALDH1A1 (0.55) | EPHX1ALDH1A1CA12CA1CA2 | |
| SCHEMBL17715691 | 0.81 | ALDH1A1 (0.42) | EPHX1ALDH1A1TP53CA12CA1 | |
| SCHEMBL8651989 | 0.81 | ALDH1A1 (0.55) | EPHX1ALDH1A1CA12CA1CA2 | |
| SCHEMBL4742218 | 0.81 | ALDH1A1 (0.42) | EPHX1ALDH1A1TP53CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1512983-A | Compounds and compositions as cathepsins inhibitors | AXYSҩ�﹫˾ | 2004-07-14 | — | — | CN | claimed |
| US-10369130-B2 | Antibacterial compounds | AZIEN DE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2019-08-06 | — | — | US | disclosed |
| CN-107936039-A | Tricyclic condensed thiophene derivant as JAK inhibitor | 因赛特公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-104918945-B | Tricyclic fused thiophene derivatives as JAK inhibitors | 因赛特公司 | 2018-01-05 | — | — | CN | disclosed |
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | disclosed |
| CN-1512983-A | Compounds and compositions as cathepsins inhibitors | AXYSҩ�﹫˾ | 2004-07-14 | — | — | CN | disclosed |
| EP-1361212-A1 | Peptide derivatives as antithrombotic agents | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| EP-0672658-B1 | Antithrombotic agents | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| CN-1364155-A | N-Cyanomethyl amides as protease inhibitors | AXYS PHARM INC (US) | 2002-08-14 | — | — | CN | disclosed |
| US-5914319-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| US-5726159-A | PEPTIDE THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| US-5707966-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5705487-A | PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369130-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | EPHX1 3980/4885ALDH1A1 3914/4885TP53 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.